ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,153.69
-0.17%
Dow Jones
39,853.87
-1.25%
Gold vs US Dollar
2,374.76
-1.41%
Brent Oil
80.20
-0.66%
Bitcoin
64,164.41
-1.85%
Pepperstone
Advertisement
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
25/07/202406:30UK RegulatoryNicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470TG:NXOANicox SA
25/07/202406:30UK RegulatoryBourse Direct : Résultats consolidés du 1er semestre 2024. Produit net bancaire consolidé en hausse de 15,8%, Résultat d’exploitation consolidé en hausse de 24,7%, Accélération du recrutement de nouveaux comptes.LSE:0DPYBourse Direct Et Bourse Discount Sa
25/07/202406:30UK RegulatoryBourse Direct : Résultats consolidés du 1er semestre 2024. Produit net bancaire consolidé en hausse de 15,8%, Résultat d’exploitation consolidé en hausse de 24,7%, Accélération du recrutement de nouveaux comptes.EU:BSDBourse Directe
25/07/202406:30UK RegulatoryNicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470LSE:0RCQNicox Sa
25/07/202406:30UK RegulatoryNicox Announces Recruitment of Last Patient in U.S. in Denali Phase 3 Trial of NCX 470EU:ALCOXNicox SA
25/07/202406:30UK RegulatoryPress Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgradedEU:SANSanofi
25/07/202406:30UK RegulatoryBGHL (GBP): NAV(s)EU:BGHSBoussard and Gavaudan Holding
25/07/202406:30UK RegulatoryCommuniqué de presse : Forte performance au deuxième trimestre soutenue par une croissance des ventes de 10% - Perspectives 2024 relevéesEU:SANSanofi
25/07/202406:30UK RegulatorySampo plc’s share buybacks 24 July 2024
25/07/202406:30UK RegulatoryBGHL (GBP): NAV(s)LSE:BGHSBoussard & Gavaudan Holding Limited
25/07/202406:30UK RegulatoryHuhtamäki Oyj’s Half-yearly Report January 1–June 30, 2024: Continued improvement in operational profitabilityTG:HUKIHuhtamaki Oyj
25/07/202406:30UK RegulatoryPress Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgradedTG:SNWSanofi
25/07/202406:30UK RegulatoryJCDecaux: H1 2024 resultsEU:DECJCDecaux SE
25/07/202406:30UK RegulatoryNicox : Recrutement du dernier patient aux Etats- Unis dans l’étude clinique de phase 3 Denali sur NCX 470EU:ALCOXNicox SA
25/07/202406:30UK RegulatoryNicox : Recrutement du dernier patient aux Etats- Unis dans l’étude clinique de phase 3 Denali sur NCX 470LSE:0RCQNicox Sa
25/07/202406:30UK RegulatoryAalberts N.V.: Aalberts delivers 15% EBITA margin in challenging marketsLSE:AALBAalberts
25/07/202406:30UK RegulatoryCommuniqué de presse : Forte performance au deuxième trimestre soutenue par une croissance des ventes de 10% - Perspectives 2024 relevéesTG:SNWSanofi
25/07/202406:30UK RegulatoryAalberts N.V.: Aalberts delivers 15% EBITA margin in challenging marketsTG:AACAAalberts NV
25/07/202406:30UK RegulatoryJCDecaux : Résultats du 1er semestre 2024EU:DECJCDecaux SE
25/07/202406:30UK RegulatoryNicox : Recrutement du dernier patient aux Etats- Unis dans l’étude clinique de phase 3 Denali sur NCX 470TG:NXOANicox SA
25/07/202406:30UK RegulatoryAalberts N.V.: Aalberts delivers 15% EBITA margin in challenging marketsEU:AALBAalberts NV
25/07/202406:30UK RegulatoryPress Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgradedBIT:SANFSanofi
25/07/202406:30UK RegulatoryBGHL (EUR): NAV(s)EU:BGHLBoussard And Gavaudan Holding Limited
25/07/202406:30UK RegulatoryCommuniqué de presse : Forte performance au deuxième trimestre soutenue par une croissance des ventes de 10% - Perspectives 2024 relevéesBIT:1SANSanofi
25/07/202406:30UK RegulatoryCommuniqué de presse : Forte performance au deuxième trimestre soutenue par une croissance des ventes de 10% - Perspectives 2024 relevéesBIT:SANFSanofi
25/07/202406:30UK RegulatoryPress Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgradedBIT:1SANSanofi
25/07/202406:30UK RegulatoryJCDecaux: H1 2024 resultsTG:DCSJCDecaux SE
25/07/202406:30UK RegulatoryJCDecaux : Résultats du 1er semestre 2024TG:DCSJCDecaux SE
25/07/202406:30UK RegulatoryBGHL (EUR): NAV(s)LSE:BGHLBoussard & Gavaudan Holding Limited
25/07/202406:25PR Newswire (US)THE LEGO GROUP UNVEILS SPACE STATION 8R1CK5 AT SAN DIEGO COMIC-CON

Your Recent History

LSE
QED
Quadrise
LSE
OCDO
Ocado
LSE
HARL
Harland & Wolff
LSE
GDR
Genedrive
LSE
GPM
Golden Prospect Precious...
LSE
IES
Invinity Energy Systems
LSE
LGEN
Legal & General
LSE
CRL
Creightons
LSE
OMI
Orosur Mining
LSE
TLY
Totally
LSE
BIRD
Blackbird
LSE
MEX
Tortilla Mexican Grill
LSE
FLTR
Flutter Entertainment
LSE
VRS
Versarien
LSE
EMG
Man
LSE
OPTI
Optibiotix Health
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved